Increasing Placebo Response in Antipsychotic Drug Trials: Let’s Stop the Vicious Circle

Dr. Leucht has served as a consultant, advisory board member, or speaker for Alkermes, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Essex Pharma, Janssen, Johnson & Johnson, Lundbeck Institute, MedAvante, Pfizer, Roche, and Sanofi-Aventis; Eli Lilly provided medication for a trial for which Dr. Leucht was the primary investigator. Dr. Heres has served as a consultant, advisory board member, or speaker or received travel funding from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Lundbeck, Novartis, Otsuka, Pfizer, Roche, and Sanofi-Aventis; he has participated in clinical trials sponsored or supported by AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Pierre Fabre, Roche, and Servier. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships. Dr. Davis reports no financial relationships with commercial interests.